486EGP
- Active ingredient
- empagliflozin+linagliptin+metformin
- Strength
- 25/5/1000 mg
- Form
- tablet
- Manufacturer
- eva pharma
- Route
- oral.solid
Uses
Adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. Empagliflozin may also reduce cardiovascular risk in eligible patients.
Do not use if
Severe renal impairment, metabolic acidosis including diabetic ketoacidosis, or hypersensitivity to any component.
Side effects
Genital and urinary infections, gastrointestinal upset, dehydration, pancreatitis, ketoacidosis, and lactic acidosis may occur.
Warnings
Monitor for lactic acidosis, ketoacidosis, renal function changes, and volume depletion.
How it works
Combines an SGLT2 inhibitor, a DPP-4 inhibitor, and metformin to reduce blood glucose through complementary mechanisms.
Storage
Store at 20–25°C and protect from excessive humidity.